

Possible role of H.pylori infection in NAFLD and Its Progression to NASH in a sector of Egyptian population

Thesis

Submitted for partial fulfillment of Master Degree
in Gastroenterology and Hepatology

Presented By

Shady Shaban Ahmed Elbasiony

M.B.B.Ch (Ain Shams University)

Under Supervision of

Prof. Dr. Khaled Hamdy Abdel Mageed

*Professor of Internal Medicine, Gastroenterology and Hepatology
Faculty of Medicine- Ain Shams University*

Dr. Nevine Ibrahim Musa

*Assistant Professor of Internal Medicine, Gastroenterology
and Hepatology*

Faculty of Medicine - Ain Shams University

Dr. Ahmed Elsaady khayyal

*Assistant Professor of Internal Medicine, Gastroenterology and Hepatology
Faculty of Medicine - Ain Shams University*

Faculty of Medicine

Ain Shams University

2019

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قالوا

سبحانك لا علم لنا
إلا ما علمتنا إنك أنت
العليم العظيم

صدق الله العظيم

سورة البقرة الآية: ٣٢



Acknowledgement

*First, thanks are all due to **ALLAH** for Blessing this work until it has reached its end, as a part of his generous help throughout our life.*

*My profound thanks and deep appreciation to **Prof. Dr. Khaled Hamdy Abdel Mageed**, Professor of Internal Medicine , Gastroenterology and Hepatology, Faculty of Medicine, Ain Shams University for his great support and advice, his valuable remarks that gave me the confidence and encouragement to fulfill this work,*

*I am deeply grateful to **Dr. Nevine Ibrahim Musa**, Assistant Professor of Internal Medicine , Gastroenterology and Hepatology, Faculty of Medicine, Ain Shams University, for her valuable efforts and eradiological expertise that were crucial to this work,*

*I am also thankful to **Dr. Ahmed Elsaady khayyal**, Assistant Professor of Internal Medicine , Gastroenterology and Hepatology, for adding a lot to this work by his experience and for his keen supervision.*

Last no words can express how thankful Iam, for my beautiful family, who supported me in all ways and by all means.

Shady Shaban Ahmed Elbasiony

List of Contents

	Page
Introduction	1
Aim of the Work	3
Review of Literature	4
Subjects and Methods	95
Results	105
Discussion	122
Conclusions	128
Recommendations	129
Summary	130
References	132
Arabic Summary	—

List of Figures

<i>Figure No.</i>	<i>Title</i>	<i>Page No.</i>
Figure (1):	Mechanisms of hepatic steatosis and influence of glucoregulatory hormones	16
Figure (2):	Histological appearance of NAFLD and NASH	30
Figure (3):	The role of endoplasmic reticulum stress in development of insulin resistance and hepatocytes apoptosis	32
Figure (4):	The role of mitochondrial autophagy in NASH	34
Figure (5):	Proposed investigation and management algorithm for NAFLD	45
Figure (6):	Showing the steps of activation of selective thyroid β receptor leading to gene expression and NAFLD	49
Figure (7):	Pathogenesis of non-alcoholic fatty liver disease (NAFLD) and potential targets for treatment of non-alcoholic steatohepatitis (NASH)	54
Figure (8):	Flowchart of the strategies of persistent infection	65

Figure (9):	Showing events leading to the successful colonization of H.Pylori	68
Figure (10):	Showing different mechanisms of H.pylori to contribute development of NAFLD	83
Figure (11):	H.Pylori exposure among the studied cases	107
Figure (12):	HOMA-IR grades among the studied cases	109
Figure (13):	Showing the grades of NAFLD fibrosis score and FIB-4 score in relation to H.pylori	113
Figure (14):	Comparison between H.Pylori exposures regarding fIB-4 score	117
Figure (15):	Comparison between H.Pylori exposure regarding NAFLD-score	119
Figure (16):	Comparison between HP exposures regarding AST	120
Figure (17):	Comparison between H.Pylori exposures regarding ALT	121

List of Tables

<i>Table No.</i>	<i>Title</i>	<i>Page No.</i>
Table (1):	Showing effects of different lipid type on the liver	27
Table (2):	NAFLD activity scoring system (NAS)	36
Table (3):	NAFLD fibrosis score	41
Table (4):	Fibrosis-4 score (FIB-4 score)	41
Table (5):	Showing (HOMA-IR) score	82
Table (6):	Demographic characteristics of the studied subjects (cases and control)	106
Table (7):	H.Pylori status among the studied cases	107
Table (8):	Laboratory findings of HOMA-IR of the studied cases....	109
Table (9):	Correlation between active, eradicated and control subjects regarding HOMA-IR	111
Table (10):	Correlation the grades of HOMA-IR in active, eradicated and controls	112
Table (11):	Liver fibrosis among the studied cases	113
Table (12):	Correlation between active, eradicated and control regarding FIB-4 score	115
Table (13):	Correlation between active, eradicated and control regarding FIB-4 score grades	116

Table (14): Correlation between active, eradicated and control regarding NAFLD-score	118
Table (15): Correlation between active, eradicated and controls regarding AST	120
Table (20): Correlation between active, eradicated and controls regarding ALT	121

List of Abbreviations

ACC1	Acetyl-CoA carboxylase 1
BabA	Blood group antigen binding adhesin A
BMD	Bone mass density
CagA	Cytotoxin-associated gene A
CCL4	Carbon tetrachloride 4
ChREBP	...	Carbohydrate response element-binding protein
CK-18	Cytokeratin-18 fragments
DNL	De novo lipogenesis
DupA	Duodenal ulcer promoting gene
GGT	Gamma glutamyl transpeptidase
GH	Growth hormone
HSL	Hormone-sensitive lipase
IGF1	Insulin-like growth factor 1
JAK	Janus kinase
MAPK	Mitogen-activated protein kinase
MCP-1	Macrophage chemotactic protein 1
NAFL	Non- alcoholic fatty liver
NAFLD	Non-alcoholic fatty liver disease

NASHNon-alcoholic steatohepatitis

OipAOuter inflammatory protein A

PAMPsPathogen-associated microbial patterns

PDFFProton density fat fraction

PNPLA3Patatin like phospholipase domain containing 3

PPAR γ Peroxisome proliferator-activated receptor
gamma

SabASialic acid-binding adhesion A

SREBP1C .Sterol response element-binding protein1C

STATSignal transducer and activator of transcription

TGF β 1Tissue growth factor

TLRsToll-like receptors

TM6SF2The transmembrane 6 superfamily member 2

TNFTumour necrotic factor

VacAVacuolating cytotoxin A

WATWhite adipose tissues

Abstract

Background: *Helicobacter pylori* (*H.pylori*) is a chronic persistent infection and its main symptoms are gastric symptoms (chronic gastritis, Peptic ulcer, gastric lymphoma and gastric cancer) but recently *H. pylori* infection implicated in extragastrointestinal diseases including (obesity, type 2 diabetes mellitus, cardiovascular disease, and liver disease). There has been a special focus on *H. pylori* infection as a risk factor for the development of nonalcoholic fatty liver disease (NAFLD). NAFLD is currently considered to be the most common liver disorder and the mechanisms of pathogenesis of underlying NAFLD remain unclear at present and therapeutic options are limited. The growing awareness of the role of *H. pylori* in NAFLD is thus important to aid the development of novel intervention and prevention strategies, because the eradication of *H. pylori* is easy and much less expensive than long-term treatment of the other risk factors. *H. pylori* infection is involved in the pathogenesis of insulin resistance (IR) which is closely linked with NAFLD. This review explaining the possible relationship between *H. pylori* and NAFLD by its role in IR.

Methods: This cross sectional, case control study was conducted on 80 patients presented with fatty or bright liver by abdominal ultrasound in Cairo hospitals (Ahmed Maher and Dar El Salam General Hospital) during the period from January 2017 to March 2018. Inclusion criteria: Patients diagnosed as fatty liver by abdominal ultrasound, Exclusion criteria: Hepatitis Viral infection (HCV Abs, HBsAg), History of drug induced hepatitis, history of alcoholism, Diabetes mellitus and history of receiving the eradication therapy of *H.pylori*. The patients divided into three groups (Active, eradicated and control) according to *H.pylori* Abs and *H.pylori* Ag in the stool. **Measurements:** HOMA-IR score, NAFLD fibrosis score and FIB4 score performed to each group.

Results: age of the studied subjects ranging between 22 and 70 years old with a mean age of 41.1 ± 9.4 years, gender of the studied subjects showed that equal incidence in both male and female. subjects with serum *H.pylori* Abs positive were 60 (75%) and 45 of them 56.2% were positive for *H.pylori* Ag in the stool (active infection) and the remainder 15 patients 18.8% were negative for Ag in the stool (eradicated infection), 20 subjects 25% were negative for *H.pylori* Abs (Control). subjects with **active** infection presented with IR were 22 (48.9%) compared with 23 in number 51.1% were normal IR and subjects with eradicated infection presented with IR were 6 (40%) compared with 9 (60%) with normal IR and subjects who were controls (uninfected) presented with IR were 12 (60%) compared with 8 (40%) with normal IR. In FIB-4 score and NAFLD-score all subjects in the study were presented with No fibrosis except that there were only 2 subjects 2.5% in the grey zone according to FIB-4 score. **Conclusion:** fatty liver was significantly more frequent in previously infected subjects (cases), insignificant correlation between *H.pylori* and insulin resistance.

Key word: ACCI, Baba, DNL, GGT, GH, NAFL

INTRODUCTION

H. Pylori is a spiral-shaped gram negative bacteria and it is the most common infection of the stomach and can colonize in the stomach since childhood and persist throughout the life causing disease symptoms mainly in adults. The most common known diseases are usually confined to the stomach in the form of:

- Chronic gastritis.
- Peptic ulcer disease
- Gastric Mucosa-associated lymphoid tissue lymphoma.
- Gastric cancer (**Amieva et al., 2008**).

Recent studies become interested more about extra-gastric effects of H. pylori such as cardiovascular, liver and biliary diseases. So, screening of this infection is recommended to apply the treatment early in life and to avoid gastric and extra gastric-effects (**Polyzos et al., 2009**). The accumulating evidence has implicated H. pylori infection in development of non-alcoholic fatty liver disease and its progression to non-alcoholic steatohepatitis. So, it is important to develop a novel interventions and prevention strategies to eradicate H. pylori infection specially that's easy and less expensive and may aid in preventing the progression of the non-alcoholic fatty liver and non-alcoholic steatohepatitis to cirrhosis (**Dunn et al., 1997**).

Non-Alcoholic Fatty Liver is a complex disease trait with pathogenesis and progression determined by genetic and environmental factors. And it is a benign state in which triglycerides accumulated in the liver and triglycerides not lipotoxic and usually associated with type 2 diabetes, obesity and insulin resistance (**Tiniako et al., 2010**).

Non-alcoholic steatohepatitis is a progression of non-alcoholic fatty liver disease in which, there is lipotoxic injury to hepatocytes by non triglyceride metabolites of free fatty acids (Hepatocyte Ballooning and lobular inflammation) (**Wallace et al., 2004**):

Insulin resistance (IR) plays a major role in developing of non-alcoholic fatty liver disease and its progression to non-alcoholic steatohepatitis (**Bonora et al., 2000**).

Insulin resistance associated with hyperinsulinemia favors accumulation of free fatty acids in the liver because of inhibition of hepatic mitochondrial beta-oxidation of free fatty acids (**fong et al., 2000**).

AIM OF THE STUDY

To study the possible role of the *Helicobacter pylori* (H.Pylori) as one of the contributing factors for development of non-alcoholic fatty liver disease (NAFLD), and its progression to non-alcoholic steatohepatitis (NASH), through its possible role in development of insulin resistance (IR) accompanied with hyperinsulinemia in a sector of Egyptian population.

NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD)

Definition

NAFLD is defined as a complex disease trait with pathogenesis and progression that determined by combination of genetic and enviromental factors associated with accumulation of hepatic fat evidenced by imaging or histological study with no coexisting cause of chronic liver disease or secondary cause of hepatic steatosis including significant alcoholic use, medications or an inherited or acquired metabalic state (**Speliotes et al., 2011**) and is divided into two subtypes:-

NAFL (non-alcoholic fatty liver) which is characterized by benign intrahepatic accumulation of triglycerides with steatosis including inflammation in at least 5% of the hepatocytes and NAFL usually does not progress to liver damage or NASH but by various mechanisms and possible insults to the liver, it may also progress into a non-alcoholic steatohepatitis (NASH) (**Chalasani,et al 2018**).

NASH (non-alcoholic steatohepatitis) which is defined as features that include steatosis, lobular and portal inflammation and liver cell injury in the form of hepatocytes ballooning (**Chalasani et al., 2012**) according to histological